At a glance
ClinicalIndex Comparison RecordPhase 1Completed· 171 enrolled
Drug / intervention
AMG 404drug
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
A Phase 1 Study to Evaluate Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of AMG 404, a Programmed Death-1 (PD-1) Antibody, in Patients With Advanced Solid Tumors
In Brief
A Phase 1 clinical trial evaluating AMG 404 for Advanced Solid Tumors. Completed, enrolled 171 participants across 34 sites in 13 countries.
Detailed Summary
To evaluate the safety and tolerability of AMG 404, a monoclonal antibody that binds to PD-1 and inhibits its engagement with ligands, in patients with advanced solid tumors.
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsAdvanced Solid Tumors
CountriesAustralia, Belgium, Brazil, Canada, Japan, Poland, Singapore, South Korea, Spain, Taiwan, Turkey (Türkiye), United Kingdom, United States
Collaborators--
Timeline
Phase 1CompletedFinished
20192020202120222023202420252026
First PostedFeb 2019
Enrollment StartMar 2019
Primary CompletionJul 2022
Study CompletionNov 2023
TodayJul 2026
First PostedFeb 25, 2019
Enrollment StartMar 5, 2019
Primary CompletionJul 19, 2022
Study CompletionNov 2, 2023
TodayJul 2, 2026
Enrollment to primary: 3.4 yearsPosted 7.4 years ago
Interventions
AMG 404drug
AMG 404 will be examined for safety, tolerability, PK, and PD of AMG 404 in subjects with advanced solid tumors.